UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

Michael D. Alvarado, MD, discusses the decision to undergo breast conservation surgery vs mastectomy following neoadjuvant breast cancer therapy.

Dr Kang discusses the significance of the FDA approval of toripalimab for nasopharyngeal carcinoma and his anticipated use of the agent.

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.

A genetic mutation that makes cancer cells hardy can be engineered into T cells, giving them superhuman strength.

Many clinicians have reported a lack of understanding of the FDA approval process and a desire for strong premarket evidence to support these approvals.

Provider and patient perspectives on why patient education about FGFRi treatment-associated adverse events and how to manage them are is essential in helping patients maintain a good quality of life and stay on treatment.

Many patients with cholangiocarcinoma being treated with FGFRi will experience stomatitis and dry mouth, but there are strategies that can help.

Experts share preventative and management strategies for nail toxicities and mouth sores that can cause significant quality of life issues for patients being treated with FGFRi.

Hyperphosphatemia is the most common AE associated with FGFRi treatments and can impact patient quality of life, but there are treatments and possible diet changes that may help mitigate this AE.

Ocular toxicities from dry eye to development of cataracts are potential risks with FGFRi treatment; providers share management strategies.

A patient with cholangiocarcinoma shares her experience while being treated with an FGFR inhibitor, as well as insights on what providers should tell their patients to help them best manage or possibly prevent these adverse events.

Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related adverse effects.

A review of how frequently adverse events from hyperphosphatemia to nail toxicities to stomatitis and more.

Provider perspectives on the importance of education patients about potential adverse events they may experience when initiating treatment with FGFR inhibitors.

A national survey conducted by UCSF researchers reveals that many physicians are unfamiliar with how the FDA regulates new drugs and medical devices.

Next-generation FGFR inhibitors show promise in early trials evaluating their efficacy and safety for the treatment of cholangiocarcinoma.

Experts discuss treatment options for cholangiocarinoma and how FGFR inhibitors have changed the treatment landscape in recent years.

Experts in treating cholangiocarcinoma share insights on when biomarker testing is needed and which biomarkers to test for.

Key opinion leaders illustrate how patients with intrahepatic cholangiocarcinoma present in a clinical setting.

The intricate web of risk factors influencing diverse forms of liver cancers are explored.

Thomas G. Martin, MD, has received a grant from the California Institute of Regenerative Medicine to produce a CAR T cell therapy for multiple myeloma.

The American Society of Clinical Oncology has elected Eric J. Small, MD, FASCO, to serve as its president for the term beginning in June 2025.

In case you missed it, here is a recap of the most popular episodes of OncLive On Air® from 2023.

Regular screenings may decrease the chance of diagnosis of advanced breast cancer in some women and lead to a 20% reduction in breast cancer mortality. However, the chances of being diagnosed with advanced breast cancer are higher among women who are Black or Hispanic/Latinx, overweight, or obese.

Laura A. Huppert, MD, discusses the impact of sequential treatment with fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy on outcomes in patients with HER2-low metastatic breast cancer, according to findings from a retrospective analysis.

Medical experts discuss the pathology of intrahepatic cholangiocarcinoma.

University of California prostate cancer experts will share clinical insights at the first annual PSMA Conference, “PSMA PET and RLT: Present and Future.”

Pembrolizumab plus olaparib did not improve progression-free or overall survival vs pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer who received induction pembrolizumab plus chemotherapy.

Arpita Desai, MD, discusses the impact that the findings from the phase 3 CONTACT-03 trial had in patients with metastatic renal cell carcinoma.

Ana Velázquez Mañana, MD, discusses findings from a study determining survivorship care needs in low-income, older patients with lung cancer.